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Introduction
The radiation burden due to
cardiovascular imaging in Europe
Cardiovascular diseases (CVDs) are the leading cause of death in
Europe (5 million deaths per year) at a cost of e196 billion in 2009.1
Imaging techniques such as computed tomography (CT), single pho-
ton emission computed tomography (SPECT), and positron emission
tomography (PET) play an increasingly important role in the diagnosis
of CVD.
Regarding myocardial perfusion imaging, scan volume has grown
rapidly worldwide over the past two decades to 15–20 million proce-
dures annually and diffusion of technology and expertise has led to its
continued adoption across the developing world.2 However, there
are concerns regarding the radiation burden associated with these
diagnostic modalities.
During the past 10 years, numerous technologies and data acquisi-
tion protocols for low-dose imaging have become available. The
implementation of these technologies is always a balance between
the long-term risk associated with exposure to ionizing radiation and
the short-term risk related to impaired diagnostic accuracy.
Furthermore, an important aspect to keep the dose as low as possi-
ble is to choose the most appropriate test for an individual patient
using the correct acquisition protocol. From a clinical point of view,
this implies to select the diagnostic test that is most likely to influence
and direct patient care to improve outcome. From a technical point
of view, this implies knowledge on differences between protocols
and applying the protocol that results in the highest image quality
with the lowest radiation exposure.3 Dose reduction is a multidisci-
plinary effort. For this reason, this article provides a consensus of
three professional associations in the field of cardiac imaging—the
European Association of Cardiovascular Imaging (EACVI), the
Cardiovascular Committee of European Association of Nuclear
Medicine (EANM), and the European Society of Cardiovascular
Radiology (ESCR)—focusing on the balance between radiation dose
and diagnostic accuracy, in agreement with the European guidelines
endorsed by the involved associations.
Radiation risk
When considering the clinical indication for diagnostic procedures
that use radiation, it is important to balance the short- and mid-term
risks of the diseases remaining undetected and untreated against the
long-term risk associated with radiation exposure.4 While ionizing
radiation applied in the context of novel imaging technologies enables
anatomical, functional, and molecular characterization of the whole
heart with high accuracy, it poses a potential health risk because it
may damage living tissues by changing cell structure and altering
DNA. Sievert (Sv) is the unit of effective radiation dose in the
International System of Units. One milliSv (mSv) corresponds to 10 J
of energy of radiation transferred to 1 g of living tissue.
The potential damage depends on not only the amount of absorbed
energy and the different types of radiation but also the susceptibility of
the tissue exposed to radiation. It has been shown that high-dose radi-
ation exposure causes adverse health effects including an increased
risk of cancer induction. Much of our knowledge about the risks from
high-dose radiation is based on studies of survivors of the atomic
bombs at Hiroshima and Nagasaki, as well as on the experiments with
fruit flies performed by Hermann Muller, which built the basis for the
linear non-threshold (LNT) model.5 The LNT model states that any
radiation dose—no matter how small—may cause cancer. The LNT
model currently still serves as the basis for international recommenda-
tions for radiation protection. This seems reasonable, despite some
uncertainties about the accurate estimation of radiation-induced can-
cer risk. These uncertainties arise from the fact that the calculations
are mainly based on data extrapolated from very high-dose exposure
and only consider radiation dose while completely neglecting dose
rate.6 Following the as low as reasonably achievable (ALARA) princi-
ple, contemporary cardiovascular examinations need to be performed
with a radiation dose as low as possible. Recent literature indicates a
median radiation exposure of 2–8 mSv for a nuclear myocardial perfu-
sion scintigraphy (MPS),2 2–5 mSv for a cardiac PET,7 and 0.5–7 mSv
for a coronary CT angiography (CCTA) scan.8 Moreover, in the set-
ting of exclusion of clinically relevant coronary artery disease, the lat-
est technologies in nuclear perfusion imaging and CT angiography
enable examinations of <1 mSv.9,10 Estimation of risk from low-dose
radiation exposure remains exceptionally difficult, but the risks are
most likely small. Prospective trials focusing on adverse events associ-
ated with radiation exposure related to diagnostic procedures are dif-
ficult to perform. Randomized prospective data will probably hardly
ever be available. A very recent study by Leuraud et al.11 followed
over 300 000 radiation-monitored workers up for a total of 8.22 mil-
lion person-years hinted a potential positive association between pro-
tracted low-dose radiation exposure and leukaemia, thus lending
support to the concept of a linear dose response at low doses. The
results from the ongoing studies, such as the Epi-CT study,12 which is
currently recruiting over one million children or young adults who
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..had CT scans in nine European countries with the aim of evaluating
the radiation-related risk of cancer, may provide more solid evidence.
State-of-the-art technologies and
their impact on radiation dose
In the last 15 years, a fast technological evolution of scanners, hard-
ware as well as software for image acquisition and reconstruction,
has allowed a dramatic improvement of efficiency and quality of car-
diac imaging resulting in progressive reduction of radiation doses to
the patient2,7,8 which are becoming comparable to natural radiation
exposure.13
This fast technological evolution may cause an imbalance between
the natural life cycle of technological equipment and the need for
updating to the state-of-the-art technology. We will summarize in
the subsequent paragraphs the major evolutions in nuclear cardiology
and cardiac CT technology, which have an impact on radiation dose
reduction (Figures 1 and 2).
New gamma camera detectors and
software dedicated to cardiac imaging
A growing number of nuclear medicine departments in Europe are
now using a new generation of gamma cameras for cardiac imaging.
In these so-called ‘CZT cameras’, the conventional sodium/iodine
(Na/I) crystal used for the detection of gamma rays has been replaced
by a cadmium–zinc–telluride (CZT) crystal. This crystal transforms
directly the signal induced by gamma rays into electric impulses with-
out the need for photodetectors. Manufacturers have taken advant-
age of these much thinner and more flexible CZT detectors to
design the gamma cameras dedicated to cardiac imaging offering a
larger surface for signal detection while focused on the heart
region.16,17 The CZT gamma cameras provide a four- to seven-fold
higher system sensitivity compared with Na/I-based cameras.18 This
increase in signal detection efficiency has translated into a significant
decrease in the dose of radiotracer required for cardiac scintigraphy.
In turn, this has resulted to lower radiation exposure of patients and
partly in shorter duration of acquisitions with preserved or even
improved image quality and increase in the detection of coronary
artery disease19 (Figure 3).
Another significant evolution has been provided by new recon-
struction algorithms. Novel iterative reconstruction methods with
resolution recovery and noise reduction provide higher image con-
trast (with sharper defects and borders) and significantly improve
image quality, particularly for low-count imaging studies from half-
and quarter-dose radiotracer protocols.20 The value of the novel
software is that existing scanners can be upgraded with advanced
software to reduce radiation dose, a much smaller capital investment
than buying a new scanner.
Positron emission tomography systems
for cardiac imaging
Thanks to the development of more efficient crystals and electronics,
cardiac PET imaging has shifted from a 2D detection mode to a 3D
detection mode.
Acquisition of PET images in a 3D mode increases the efficiency of
signal detection by a factor of 2 and therefore requires, for similar
image quality, the injection of only half of the dose of radiotracer for-
merly required in 2D mode.21,22 PET images require correction for
tissue attenuation, which is currently provided by using maps derived
from low-dose CT acquisitions. This low-dose CT-related radiation
exposure adds up to that from PET. Thus, PET–CT examination will
most likely benefit from current progresses in CT image reconstruc-
tion to reach lower levels of radiation exposure. This is even more
important in hybrid cardiac PET/CT imaging that is used to combine
PET and coronary CT angiography information on myocardial func-
tion and coronary anatomy, which will benefit even more from CT
dose-saving protocols.23
Figure 1 Bar graph illustrating the average effective radiation doses of cardiac CT applying the various radiation dose reducing algorithms. Adapted
from reference.14
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Figure 2 Recommended radiotracer doses for MPI conventional scanners (white bar) and for scanners with new softwares and/or hardwares
(grey bar). Full-dose PET radiotracer is used for 2D imaging and half-dose for 3D imaging; typically, equal dose of radiotracer is administered for rest
and for stress PET MPI. Estimated dose is effective dose multiplied by administered activity. Dose is calculated for rest and stress scans separately,
considering a single day examination. Adapted from reference.15
Figure 3 A 60-year-old gentleman with typical angina. A single-day stress–rest low-dose protocol with 99mTc-tetrofosmin was performed, inject-
ing 130 MBq at peak of exercise stress test and 390 MBq at rest. Stress and rest images were acquired for 6 and 5 min, respectively. CZT images
reveal the presence of a reversible perfusion defect involving the inferoseptal wall, the inferior wall, the distal portion of the anteroseptal wall, and
the apex.
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The emerging digital PET detector technology based on silicon
photomultipliers will allow for a further substantial reduction of
injected dose and therefore decrease radiation exposure. Recently, a
new generation of scanners has entered the clinical arena, integrating
a magnetic resonance (MR) with a PET device into a hybrid PET/MR
scanner.24,25 The preliminary results show that attenuation maps can
be obtained from MR, avoiding the need for CT attenuation maps,
therefore reducing the ionizing radiation to the patient.26
Cardiac computed tomography
State-of-the-art cardiac CT scanners are equipped with 64 or more
detector rows. Several technological advances can and should be
used to acquire cardiac CT data sets at low radiation doses. Among
them, fast scanner rotation with high temporal resolution has been
important, as it permits prospectively electrocardiographically
(ECG)-triggered image acquisition. In fact, it has been the introduc-
tion of prospective ECG triggering,27 which has paved the way for
low radiation dose scanning in daily practice. Although this technique
has less flexibility regarding the cardiac phase in which images are
reconstructed, when compared with helical or spiral acquisition pro-
tocols with retrospective ECG gating, it results in substantially lower
dose. Prospectively ECG-triggered high-pitch spiral acquisition pro-
tocols can further reduce the dose.28 All these lower dose acquisition
protocols require lowering of the heart rate.29,30 The fact that mod-
ern X-ray tubes generate higher tube currents at the same potentials
can also be used to reduce patient radiation exposure: low tube
potentials—such as 70 or 80 kV—substantially reduce dose com-
pared with the standard use of 100 or 120 kV, whereas high tube cur-
rents compensate for increased image noise.31 Dedicated roentgen
tube filters can further reduce dose by effective shielding and modifi-
cation of the X-ray spectrum. Various types of tube current modula-
tion, to continuously adjust the tube output depending on the type
and amount of tissue to be penetrated, can further reduce dose.
Finally, iterative reconstruction algorithms, which improve image
quality compared with the filtered back-projection techniques, allow
for cardiac imaging at lower radiation exposure (Figure 4).32–34
A brief description of the main metrics used for characterization of
CT radiation dose is depicted in Table 1.
Changed protocols, which have
impact on dosimetry and patients
Appropriate selection of radiotracer and acquisition protocols is crit-
ical in reducing patient radiation dose. All these variables must be
considered while keeping in mind that diagnostic accuracy of the
imaging test should be maintained (Table 2). As a good clinical prac-
tice, the overall radiation dose to the patient resulting from the given
imaging procedure should be clearly indicated in the clinical report as
recommended by current international procedures.3
Single photon emission computed
tomography protocols and tracers
Currently, it is not possible to issue precise recommendations
regarding the doses of radiotracers for SPECT myocardial perfusion
imaging (MPI) due to the lack of strong evidence linking a better per-
formance of the test to specific injected doses. The dose of radio-
tracer to be administered is a compromise between image quality
and radiation exposure and depends on patient characteristics (e.g.
body weight), choice of radiopharmaceutical (99mTc compounds or
201Tl chloride),35 acquisition protocol (1 day or 2 days protocols,
imaging time, pixel size, and gated acquisition), and the type of equip-
ment (multiple head scintillation camera or a camera based on CZT
detectors).
Figure 4 Ultralow-dose coronary CTA performed in a 67-year-old female (BMI 20) with a 320-row multidetector CT scanner, using a single heart-
beat acquisition technique. By combining an 80-kVp tube voltage with third-generation iterative reconstructions, a sub-mSv radiation dose was
obtained (0.7 mSv) with a high diagnostic quality of the examination. Volume rendering (A) and curved planar reconstruction (B) images show the
presence of a high-risk, eccentric, soft tissue lesion in the proximal right coronary artery causing a high-grade stenosis.
290 A. Gimelli et al.
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For example, a weight- or body mass index (BMI)-based adjusted
SPECT radiotracer dose may be better than a fixed dose to balance low
radiation (58% radiation dose reduction) with optimal image quality.36
99mTc agents are to be preferred over 201Tl because of their
shorter half-life, significantly lower effective dose, and superior image
quality. Based on the current models for the calculation of absorbed
effective doses,37 for 99mTc-labelled tracers, the effective dose for a
full stress–rest protocol with 1000 MBq is approximately of 6–
7 mSv.6 For a stress–rest protocol using 111 MBq of 201Tl (74 MBq
for stress and 37 MBq at rest), the effective dose (11 mSv) is
increased of almost a factor of 2.
Stress-first enabling stress-only MPI using 99mTc tracers can signifi-
cantly reduce the radiation dose compared with standard dose rest–
stress MPI protocols. If the stress MPI results are normal, the rest
scan can be omitted, with significant savings in cost, time, and radio-
tracer exposure to the patient (35% dose reduction) and to the labo-
ratory staff (40% dose reduction).38 Prone imaging can be used as an
alternative strategy for troubleshooting attenuation-dependent infe-
rior wall perfusion defects. The attenuation correction CT scan
results in an additional dose of 0.5–1.0 mSv. However, attenuation
correction using radionuclide or CT-based transmission scans may
reduce the need for rest MPI imaging in a significant percentage of
patients, thus limiting the overall radiation dose.39,40 In patients with
increasing body weight, such as in obesity or body habitus in women,
the image quality may be limited, reducing the possibility to perform
routinely stress-only protocol.
The technology of the gamma cameras is another variable that
may help reducing the radiation dose. Low radiotracer dose proto-
cols (half-dose or less than half-dose) using novel scanners, collima-
tors, or software are increasingly utilized. Camera systems based on
new technologies (e.g. CZT cameras) have improved count sensitiv-
ity for the detection of gamma rays. The increased sensitivity enables
shorter image acquisition duration.12,41–44 Nevertheless, in light of
the ALARA principle, this improved sensitivity should preferentially
be used to reduce the amount of injected dose preserving the image
quality.45 Effective doses below 2 mSv can be achieved by administer-
ing low-dose 99mTc tracers (lower than 148 MBq) and combining
stress-only protocols with new scanner technologies.
Taken together, there are plenty of opportunities to reduce
patient radiation burden without major impact on image quality and
Table 2 Practical ways to reduce radiation exposure
Before the test • Consider implementing new imaging technologies allowing for radiation exposure
• Select the optimal test for the individual patient and situation, guided by clinical guidelines and appropriateness
criteria
• Check for recently performed cardiac evaluations to avoid duplicate testing
• If the clinical question is not clear or the test ordered is not the most appropriate test, discuss with the referring
physician (consider a multidisciplinary approach)
• Plan a personalized imaging protocol according to age, weight, and estimated prevalence of CAD
• Avoid repeating examinations as a routine for unselected patients
At the time of the test Myocardial scintigraphy: check the possibility to perform stress-only acquisition
After the test (These recommendations do not reduce radiation exposure, but make others aware for potential future radiation
exposure)
• Report dose of radiotracers and total radiation exposure
• Provide easy access to imaging and reports
• Monitor trends in radiation exposure at your laboratory and compare with other laboratories
Table 1 Description of the main metrics used for characterization of CTradiation dose
Computed tomography
dose index (CTDI)
Area under the radiation dose profile for a single rotation and fixed table position along the axial direction of the
scanner divided by the total number of detectors for slice thickness and is expressed in coulomb/kg
CTDI100 Integrated radiation dose from acquiring a single scan over a length of 100 m
CTDIw Average radiation dose to a cross-section of a patient’s body determined with the equation CTDIw=2/3CTDI100
at peripheryþ1/3CTDI100 at centre
CTDIvol Average radiation dose over the volume scanned determined by the equation CTDIvol=CTDIw/pitch, where pitch
is defined as table movement expressed in millimetres for each 360 gantry rotation, divided by the product of
the number of slices and slice width. It is measured in milligray
Dose length product (DLP) Integrated radiation dose for a complete CT examination measured in milligraycentimetres and calculated by the
formula DLP=CTDIvollength irradiated
Effective dose (ED) Measured as the product between DLP and k, the region-specific conversion factor
Radiation dose reduction in nuclear cardiology and CT imaging 291
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..thereby maintaining diagnostic accuracy.38,41–43,45 Efforts should be
directed towards reducing radiation exposure by taking advantage of
the recent development in SPECT technology.
The key points include main steps to set-up a nuclear cardiology
protocol to minimize the radiation exposure.
Positron emission tomography protocols
and tracers
Estimated whole-body effective radiation dose is directly related to
the half-life of the radiotracer and dose of radiotracer administered.
In general, PET myocardial perfusion tracers have the advantage of
their short to very short half-lives.
For the evaluation of myocardial perfusion 82Rb and 13N-ammonia,
the most commonly utilized tracers for clinical imaging provide high
image quality and low radiation exposure. Positron emission
tomography protocols allow for quantitation of absolute myocardial
blood flow (MBF) in mL/min/g, and MBF reserve providing additional
relevant information in different patient populations46–50 and for
selected clinical conditions (balanced myocardial ischaemia and
microvascular disease).17 O-water is the gold standard radiotracer
for the measurement of MBF with PET and provides parametric
quantitative representation of MBF with low radiation exposure.
A complete stress–rest study can be performed with a total radiation
exposure of 2–4 mSv for 13N-ammonia, 3–5 mSv for 82Rb and
1–2 mSv for 15O-water. New 18F-labelled PET radiotracers for MPI
are currently under evaluation and can be used with exercise stress
testing because of their longer half-life and longer retention times.51
The use of 13N-ammonia and 15O-water requires an on-site cyclo-
tron for the synthesis of radiotracer. 82Rb can be produced in a gen-
erator, which is relatively cheap even if the monthly costs of
precursor are high requiring high patient throughput to be cost-
effective. As for SPECT, a weight- or BMI-based adjusted PET radio-
tracer dose is recommended to reduce radiation dose and preserve
optimal image quality.
Moreover, as recently demonstrated by Danad et al.,52 further
reduction of radiation exposure can be achieved by a stress-only pro-
tocol. The use of a quantitative cut-off for absolute hyperaemic myo-
cardial blood flow may provide even a superior accuracy for
diagnosing haemodynamically significant coronary artery disease
(CAD) when compared with quantification of flow reserve that
requires rest/stress protocol. For evaluation of myocardial viability,
the typical protocol includes a PET perfusion study and a PET meta-
bolic study using 18F-fluorodeoxyglucose (18 F-FDG). A strategy to
reduce radiation exposure is the use of 18F-FDG without PET MPI,
as preserved uptake of FDG can be regarded as a sign of viability.53
A typical 18 F-FDG cardiac study results in3–5 mSv.
In PET/CT scanners, accurate attenuation correction of cardiac
PET image is provided by CT, with a small increase in radiation dose.
Using a single CT scan for attenuation correction of multiple PET
acquisitions can further reduce the global dose.54 Recent develop-
ments in PET technology (e.g. 3D detection mode and silicon photo-
multipliers) may allow to further reduce the injected dose and hence
the radiation exposure.
The key points include main steps to set-up a cardiac PET protocol
to minimize the radiation exposure.
Computed tomography protocols
Until approximately 2006, most coronary CT angiograms were
acquired using a retrospectively ECG-gated spiral scan mode. The
principle of this scan mode is the continuous table movement and
data acquisition over several cardiac cycles, after which cardiac
phase-consistent projections are combined using a recorded rhythm
trace to reconstruct the images. For image reconstruction, the
desired phase of the cardiac cycle is specified and only X-ray data
acquired during this phase is used for image reconstruction while the
remaining data are often discarded. If desired, multiple reconstruc-
tions at various time points of the cardiac cycle can be obtained. This
allows for selecting the phase with least motion artefacts and, within
limits, permits to correct for arrhythmias and other artefacts.
The major drawback of this protocol is the high radiation exposure
caused by temporal and spatial oversampling. Modifications have
been designed to reduce overall radiation exposure. ECG-triggered
X-ray tube current modulation is an algorithm that can reduce the
tube output during the phases that are less likely to be used for the
reconstruction.
This approach is effective in terms of radiation dose reduction and
should be considered as a standard practice with retrospectively
gated spiral CT protocols.
In patients with stable and low heart rates (usually below 65
b.p.m.), prospectively ECG-triggered axial scan protocols, also
known as ‘sequential’ or ‘step-and-shoot’ protocols, have largely
replaced spiral protocols. The advantage of the axial scan protocol is
that exposure only occurs during the phase that is intended for
reconstruction, minimizing the overall radiation exposure. Also the
z-axis oversampling is less using axial scan protocols. The drawback is
......................................................................................................
Best practice Dose (mSv)
Prefer radiotracers with low radiation
exposure 99mTc (stress/rest protocol,
4 mCi/12 mCi, respectively)
2–8
Check the possibility to perform stress-only
acquisition (4 mCi)
<_2
Use weight-based radiotracer doses
Appropriate use of attenuation correction 0.5–1
Avoid 201Tl (stress/rest protocol) >8
Avoid dual isotope imaging >8
......................................................................................................
Best practice Dose
Check the possibility to perform stress-only
acquisition (99mTc tracers, 4 mCi)
50% dose reduction
Use weight-based radiotracer doses
Appropriate use of attenuation correction 0 5–1 mSv
Avoid dual isotope imaging of viability
when possible (FDG only, 10 mCi)
3–5 mSv
Know the radiation dose associated with
each radiotracer in a typical perfusion study
13N-ammonia (10 mCi) (stress or rest) 2 mSv
15O-water (24 mCi) (stress or rest) 1.5 mSv
82Rubidium (20 mCi) (stress or rest) 2.5 mSv
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that it relies on a regular and relatively low heart rate. Depending on
the system, no alternative cardiac phases may be available in the case
of suboptimal image quality. More recent systems operate axial scan
protocols that allow for prolonged sampling and reconstruction of
additional phases (also known as ‘padding’) and are also equipped
with arrhythmia detection and handling algorithms. In the event of an
irregular heartbeat, the acquisition at a given location is interrupted
and/or repeated.
An additional strategy to reduce the radiation exposure is based on
reduction of scan time. Wide detector array scanners (256–320 rows)
and second- and third-generation dual-source CT scanners with high-
pitch spiral scan protocols allow for complete coverage of the heart in
a single gantry rotation. Single-beat acquisition avoids ‘step’ or ‘mis-
alignment’ artefacts seen on image acquisition during multiple heart-
beats and is generally associated with a lower radiation exposure.
Radiation exposure is very low due to the lack of oversampling.
The prospectively ECG-triggered high-pitch spiral protocol on dual-
source scanners results in substantially lower doses but requires a
slow and regular heart rhythm.55,56
Absorbed doses from CT coronary angiography (CTCA) depend
on the system and imaging protocol used and can be estimated
between 2 and 5 mSv using commonly available single-source 64-slice
CT scanners with a prospectively ECG-triggered step-and-shoot
acquisition protocol.57,58 In suitable patients, the acquisition proto-
cols allowed by the newest CT hardwares and softwares enable even
lower absorbed doses <1 mSv.9,28
Finally, if the lowering of tube voltage is a very effective radiation
dose-saving strategy in CCTA due to the correlation between effec-
tive dose and the square of tube voltage, this is not possible for cal-
cium score. Indeed, the change of scan parameter can influence the
CAC value, and therefore, in this setting, only tube current optimiza-
tion can be performed.
The key points include main steps to set-up a CT protocol to mini-
mize the radiation exposure.
Fusion computed tomography/single
photon emission computed tomography–
computed tomography/positron
emission tomography imaging
‘Fusion’ or ‘hybrid’ imaging describes the integration of complemen-
tary imaging modalities to improve yield, accuracy, clinical, and
prognostic impact of single imaging modalities. Early studies dating
back nearly a decade have reported radiation doses from hybrid CT/
SPECT imaging in the range of 15–25 mSv59 and in the range of 9–
15 mSv for hybrid CT/PET imaging.23 Due to the added radiation
exposure, sensible and careful patient selection for hybrid imaging
procedures remains crucial. Even if large trials have yet to be con-
ducted, it seems reasonable to address to hybrid imaging studies for
those patients in whom perfusion defect allocation and assessment of
the haemodynamic significance of individual lesions will play a deter-
mining role for further treatment and particularly for guiding revascu-
larization procedures.60,61 A potential strategy to reduce the added
radiation exposure is to perform sequential imaging studies, where
CTCA is used as a gatekeeper for SPECT or PET imaging.62 As previ-
ously described, a number of extremely effective strategies and pro-
tocols are now available for reducing radiation exposure of both
radionuclide imaging and CTCA. When all the aforementioned dose
reduction strategies are exploited, full and comprehensive hybrid
imaging studies may be obtained at a cumulative radiation dose as
low as 4 mSv.63 At such doses, hybrid imaging can be considered in
wider patient populations with a very acceptable safety profile.
Appropriate clinical use of non-
invasive cardiac imaging for reduc-
ing global radiation exposure
Nuclear and CT imaging are included in the management flow charts
of patients with different cardiovascular diseases providing unique or
alternative information when compared with other imaging modal-
ities. Current international guidelines and recommendations include
nuclear cardiology techniques and cardiac CT as appropriate modal-
ities for different clinical scenarios (see Supplementary material
online, S1). Nevertheless, selection of functional cardiovascular imag-
ing by nuclear modalities and anatomical imaging by CT depends on
multiple factors including the clinical question, the age of the patient,
the estimated pre-test probability of the disease, costs, availability
and local expertise for each imaging technology, physician preferen-
ces, and patient convenience.64 Some of these factors determine the
overall radiation exposure that the patient will receive and, following
the most recent clinical guidelines from the European Society of
Cardiology (ESC) can be favourably modified taking into account the
ALARA principle.
However, as underlined in a recent joint position document on
three main different associations of the ESC: ‘All other considerations
being equal, it is not recommended to perform tests involving ioniz-
ing radiation when the desired information can be obtained with a
non-ionizing test with comparable accuracy. If you perform a test
that utilizes ionizing radiation, choose the one with the lowest dose
and be aware of the many factors modulating dose’.3 In the current
ESC guidelines on stable CAD,64 stress echocardiography, stress
MRI, and stress MPS have the same level of recommendation for diag-
nosis and are considered as equally valid alternatives and should be
taken into account to reduce radiation exposure. However, it should
also be considered that imaging tests may carry risks not only related
with radiations such as those associated with stressors, contrast
agents, or other energy sources. For example, the induction of DNA
......................................................................................................
Perform scan
length
optimization
Perform a topogram before the con-
trast-enhanced scan to minimize scan
length and overall ED
Set-up tube voltage
and tube current
Consider a trade-off between higher image
noise and lower contrast resolution
For clinical practice: tube voltage of 100 and
120 kVp for patients with BMI <30 and
>30 kg/m2, respectively
Choice of ECG
triggering
High heart rate: retrospective ECG triggering
with tube current modulation
Low heart rate: prospective ECG-triggering
Last-generation scanner: single-beat acquisition
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double-strand breaks has been described after exposure to non-
ionizing radiation from cardiac MR scanning65,66 even if its impact on
long-term risk is not clear and has not yet been sufficiently explored.
The knowledge of all advantages and pitfalls for each imaging techni-
que should be well known to select the best one for each patient.
A brief description of the role of nuclear diagnostic imaging in several
clinical scenarios, as indicated in the current ESC guidelines and recom-
mendations, is summarized in Supplementary material online, S1.67–77
Impact on costs
Total expenditures related to advanced imaging show an increasing
trend in Europe, raising concerns among health care providers.78 As
a consequence, evaluation of diagnostic tests is shifting to an assess-
ment of their effect on clinical outcomes in relation to treatment and
in particular cost-effectiveness rather than on their diagnostic accu-
racy alone. Although most of the publications using non-invasive test-
ing indicate cost-effectiveness over strategies without non-invasive
tests, the overall published data are conflicting, particularly regarding
the question which non-invasive strategy is the most cost-effective.
Moreover, the definition of effectiveness often includes diagnostic
accuracy or downstream utilization of resources and rarely more rel-
evant endpoints such as efficacy on clinical outcome. In addition, the
definition of costs generally does not include those related with
missed/over diagnosis or with the risks potentially associated with
the procedure.
There are no studies available on the cost-effectiveness of radia-
tion dose reduction strategies. Due to the present uncertainty of the
risks associated with low radiation doses, the results of long follow-
up studies assessing the impact on health and related costs are essen-
tial. However, lower dosages of the specific and most often expen-
sive radiopharmaceuticals will most likely result in lower costs even if
this assumption is dependent on local and national differences. In
contrast with nuclear cardiology procedures, it is more difficult to
predict the effects on costs in relation to a reduction in radiation
dose with CT-driven protocols.
Conclusions
The increasing awareness of procedure-associated radiation has trig-
gered the introduction of novel imaging protocols, and the develop-
ment of new imaging technologies aiming at lowering radiation dose
with further optimization of image quality. The state-of-the-art
nuclear cardiology and cardiac CT imaging require embracing best
practices for appropriate patient selection, patient-centred imaging
protocols, use of novel protocols for traditional scanners, and adop-
tion of laboratory practices to reduce lifetime radiation exposure for
patients and staff members. This strategy requires a close collabora-
tion between the three main European Societies (EACVI, EANM, and
ESCR) to disseminate and educate the different myocardial imaging
professionals as well as the referring clinical cardiologists.
Supplementary material
Supplementary material is available at European Heart Journal online.
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